Register Now: Beyond EDC: Designing a Connected Data Strategy for Predictive Clinical Development
Commentary|Videos|December 17, 2025

Rethinking Operational Models to Reduce Site Burden in 2026

Examine how evolving sourcing strategies, functional standardization, and system choices can help sponsors support sites more effectively while minimizing operational switching and complexity.

In a recent video interview with Applied Clinical Trials, Kevin Williams, EVP and Chief Strategy Officer at Ledger Run, discussed how sponsors must rethink operational strategies in 2026 to better support clinical trial sites amid rising complexity. He explained why sourcing models, system design, and workflow automation must be evaluated together to reduce operational switching and site burden. Williams also outlined how sponsors can introduce new engagement tools without overwhelming sites, emphasizing neutrality-first adoption and consistency across processes. He explored how AI-enabled workflows can automate existing processes rather than impose new ones, and concluded by identifying the metrics sponsors and CROs should track to assess whether site support investments are improving performance, satisfaction, and long-term collaboration.

The below interview transcript was lightly edited for clarity.

ACT: What key operational changes are needed in 2026 to truly support sites rather than overwhelm them with new tools or processes?

Williams: Yeah, I think from an operational perspective, it depends what aspects you’re looking for. On the trials, there could be a number of things that could contribute to different changes. I think one of the key things that people look at is, one, how do I deliver the service? So is that a functional standardization?

In our particular space, it’s usually, do I source it to CROs, or to multiple CROs, or do I use a more functional model? So when you think about operational changes, do I change my approach functionally to do it? And then I think the other component of that is, do I change my systems or applications, or is there a better way to do it? And those two things aren’t mutually exclusive. It may, in fact, be a combination.

What we’ve definitely seen is that sponsors are exploring different ways in how they approach their utilization of CROs and other service providers. We’ve definitely seen a trend toward bringing things in house. And what does in house mean? Does in house mean functional sourcing, or does it mean a new system, or some combination of both?

I think the other key thing on that is really related to operational switching, and I’ll talk about that a little bit later too. Sites traditionally have challenges working with a lot of different sponsors and CROs. Whether it’s different processes from one sponsor to the next, or different systems, they deal with a lot of switching burden—having to log into different systems and things like that. So those are things that people need to be aware of when making choices about changes.


Related to this article

© photon_photo - © photon_photo - stock.adobe.com
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
What Expanding AI Ecosystems Mean for Sponsor Complexity and Oversight
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
The Human Side of Clinical Trials: Why Fuzzy Mental Models Undermine Clinical Trial Execution
In Episode 3 of The Human Side of Clinical Trials, hosts Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., speak with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about why a well-written protocol doesn’t always translate into consistent execution, and how designing for the way people actually think and learn can reduce site burden and the need for costly unlearning.
Where AI Governance in Clinical Development Falls Short
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, identifies three recurring failure modes in AI governance frameworks—and explains why responsible AI must be an ongoing operating discipline, not a one-time approval gate.